Please assess the completion status of the following clinical trial:

Trial Title: Clarithromycin as Adjuvant to Periodontal Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Generalized Aggressive Periodontitis~* presence of ≥20 teeth~* presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them)~* good general health~* \<35 years of age~* agree to participate in the study and sign a written consent~Exclusion Criteria:~* pregnant or lactating~* suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease~* received antimicrobials in the previous 6 months~* taking long-term anti-inflammatory drugs~* received a course of periodontal treatment within the last 12 months~* smoked

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- clarithromycin group (Type: ACTIVE_COMPARATOR): 20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
- placebo group (Type: PLACEBO_COMPARATOR): 20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).